Alexander C Ford1, Nicholas J Talley. 1. Leeds Gastroenterology Institute, D Floor, Clarendon Wing, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK. alexf12399@yahoo.com
Abstract
BACKGROUND: The causes of irritable bowel syndrome (IBS) remain obscure. Some investigators have proposed chronic low-grade mucosal inflammation as a potential etiological factor. We performed a systematic review to examine this issue in detail. METHODS: MEDLINE, EMBASE, and EMBASE classic were searched up to December 2010 to identify studies of case-control design applying tests for low-grade inflammation to either full-thickness intestinal or endoscopic mucosal biopsies from patients with IBS. Controls were required to be healthy individuals, or asymptomatic patients undergoing investigation for reasons other than the reporting of upper or lower gastrointestinal symptoms. Individual study results were summarized descriptively. RESULTS: The literature search identified 1388 citations, of which 16 studies were eligible for inclusion. Individual study results were diverse, partly as a consequence of the different surrogate markers for inflammatory mechanisms studied. Mast cells, T lymphocytes, B lymphocytes, and mucosal cytokine production all appeared altered among cases with IBS in individual studies, while no study demonstrated a significant difference in numbers of plasma cells, neutrophils, or eosinophils. Some studies suggested a relationship between mast cell abnormalities and symptom severity and frequency, as well as co-existent fatigue and depression. Studies were limited by the lack of comparability of controls, and the fact that most were conducted in highly selected groups of patients with IBS. CONCLUSIONS: Low-grade mucosal inflammation, particularly mast cell activation, may be a contributory factor in the pathogenesis of IBS. Mast cell stabilizers warrant further assessment as a potential therapy in the condition.
BACKGROUND: The causes of irritable bowel syndrome (IBS) remain obscure. Some investigators have proposed chronic low-grade mucosal inflammation as a potential etiological factor. We performed a systematic review to examine this issue in detail. METHODS: MEDLINE, EMBASE, and EMBASE classic were searched up to December 2010 to identify studies of case-control design applying tests for low-grade inflammation to either full-thickness intestinal or endoscopic mucosal biopsies from patients with IBS. Controls were required to be healthy individuals, or asymptomatic patients undergoing investigation for reasons other than the reporting of upper or lower gastrointestinal symptoms. Individual study results were summarized descriptively. RESULTS: The literature search identified 1388 citations, of which 16 studies were eligible for inclusion. Individual study results were diverse, partly as a consequence of the different surrogate markers for inflammatory mechanisms studied. Mast cells, T lymphocytes, B lymphocytes, and mucosal cytokine production all appeared altered among cases with IBS in individual studies, while no study demonstrated a significant difference in numbers of plasma cells, neutrophils, or eosinophils. Some studies suggested a relationship between mast cell abnormalities and symptom severity and frequency, as well as co-existent fatigue and depression. Studies were limited by the lack of comparability of controls, and the fact that most were conducted in highly selected groups of patients with IBS. CONCLUSIONS: Low-grade mucosal inflammation, particularly mast cell activation, may be a contributory factor in the pathogenesis of IBS. Mast cell stabilizers warrant further assessment as a potential therapy in the condition.
Authors: Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson Journal: Gastroenterology Date: 2002-06 Impact factor: 22.682
Authors: Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle Journal: J Clin Invest Date: 2007-02-15 Impact factor: 14.808
Authors: Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara Journal: Am J Gastroenterol Date: 2009-01-13 Impact factor: 10.864
Authors: Alexander C Ford; David Forman; Alastair G Bailey; Anthony T R Axon; Paul Moayyedi Journal: Am J Gastroenterol Date: 2008-03-26 Impact factor: 10.864
Authors: Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper Journal: J Gastroenterol Date: 2014-01-17 Impact factor: 7.527
Authors: Rebeca Martín; Florian Chain; Sylvie Miquel; Jane M Natividad; Harry Sokol; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán Journal: Hum Vaccin Immunother Date: 2014-04-14 Impact factor: 3.452